PubRank

Josephine M Forbes

Author PubWeight™ 62.57‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 2003 2.69
2 Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2007 2.51
3 Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008 2.41
4 Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003 2.10
5 High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009 2.00
6 Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006 1.88
7 RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 2009 1.72
8 Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int 2011 1.63
9 Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int 2010 1.57
10 AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 2007 1.49
11 Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study. J Vasc Surg 2009 1.41
12 Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler Thromb Vasc Biol 2005 1.35
13 Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 2004 1.28
14 Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004 1.15
15 Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005 1.14
16 Advanced glycation end products are direct modulators of β-cell function. Diabetes 2011 1.14
17 Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 2006 1.13
18 Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J Hypertens 2010 1.12
19 Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 2002 1.07
20 Advanced glycation end products and diabetic nephropathy. Am J Ther 2005 1.05
21 Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 2004 1.04
22 Coming full circle in diabetes mellitus: from complications to initiation. Nat Rev Endocrinol 2013 1.01
23 Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med 2011 0.99
24 Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 2003 0.98
25 Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets. Curr Drug Targets 2009 0.97
26 Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2009 0.96
27 Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system. J Hypertens 2005 0.94
28 The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. Am J Physiol Renal Physiol 2010 0.92
29 Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. Am J Physiol Endocrinol Metab 2008 0.92
30 MKK3 signalling plays an essential role in leukocyte-mediated pancreatic injury in the multiple low-dose streptozotocin model. Lab Invest 2008 0.91
31 Advanced glycation: implications in tissue damage and disease. Protein Pept Lett 2008 0.90
32 Oxidative stress and advanced glycation in diabetic nephropathy. Ann N Y Acad Sci 2008 0.89
33 Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. Circ Res 2013 0.89
34 Renal microvascular injury in diabetes: RAGE and redox signaling. Antioxid Redox Signal 2007 0.87
35 Heat shock protein expression in diabetic nephropathy. Am J Physiol Renal Physiol 2008 0.87
36 Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more? Ann N Y Acad Sci 2005 0.86
37 Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. Curr Opin Pharmacol 2013 0.86
38 High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction. J Mol Endocrinol 2005 0.84
39 Reduced tubular cation transport in diabetes: prevented by ACE inhibition. Kidney Int 2003 0.84
40 c-Jun NH2-terminal kinase activity in subcutaneous adipose tissue but not nuclear factor-kappaB activity in peripheral blood mononuclear cells is an independent determinant of insulin resistance in healthy individuals. Diabetes 2009 0.83
41 Advanced glycation end products as environmental risk factors for the development of type 1 diabetes. Curr Drug Targets 2012 0.83
42 The role of advanced glycation in reduced organic cation transport associated with experimental diabetes. J Pharmacol Exp Ther 2004 0.82
43 Obesity-induced renal impairment is exacerbated in interleukin-6-knockout mice. Nephrology (Carlton) 2012 0.82
44 Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content. Nephrology (Carlton) 2013 0.82
45 SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY): a protocol of placebo-controlled randomised cross-over trial. BMC Nephrol 2014 0.81
46 Plasma advanced glycation end products (AGEs) and NF-κB activity are independent determinants of diastolic and pulse pressure. Clin Chem Lab Med 2014 0.80
47 A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches? Am J Nephrol 2009 0.80
48 The relationship between heat shock protein 72 expression in skeletal muscle and insulin sensitivity is dependent on adiposity. Metabolism 2010 0.79
49 Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes. Diabetologia 2014 0.79
50 Temporal increases in urinary carboxymethyllysine correlate with albuminuria development in diabetes. Am J Nephrol 2011 0.79
51 Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man. Am J Nephrol 2011 0.78
52 Ramipril prevents microtubular changes in proximal tubules from streptozotocin diabetic rats. Nephrology (Carlton) 2003 0.78
53 Agents in development for the treatment of diabetic nephropathy. Expert Opin Investig Drugs 2005 0.77
54 Impairment of Liver Glycogen Storage in the db/db Animal Model of Type 2 Diabetes: A Potential Target for Future Therapeutics? Curr Drug Targets 2015 0.76
55 Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy. Am J Nephrol 2010 0.76
56 Reversible angiotensin II-mediated albuminuria in rat kidneys is dynamically associated with cytoskeletal organization. Nephron Physiol 2003 0.76
57 Modulation of the cellular expression of circulating advanced glycation end-product receptors in type 2 diabetic nephropathy. Exp Diabetes Res 2011 0.76
58 Additive effects of hypertension and diabetes on renal cortical expression of PKC-alpha and -epsilon and alpha-tubulin but not PKC-beta 1 and -beta 2. J Hypertens 2003 0.75
59 Insulin infusion reduces hepatocyte growth factor in lean humans. Metabolism 2012 0.75
60 Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome? Ann N Y Acad Sci 2008 0.75
61 Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes? Ann N Y Acad Sci 2005 0.75
62 Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep 2016 0.75